ImmunoPET imaging of CD38 in murine lymphoma models using 89Zr-labeled daratumumab

Lei Kang, Dawei Jiang, Christopher G. England, Todd E. Barnhart, Bo Yu, Zachary T. Rosenkrans, Rongfu Wang, Jonathan W. Engle, Xiaojie Xu, Peng Huang, Weibo Cai*

*Corresponding author for this work

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

Purpose: CD38 is considered a potential biomarker for multiple myeloma (MM) and has shown a strong link with chronic lymphocytic leukemia due to high and uniform expression on plasma cells. In vivo evaluation of CD38 expression may provide useful information about lesion detection and prognosis of treatment in MM. In this study, immunoPET imaging with 89Zr-labeled daratumumab was used for differentiation of CD38 expression in murine lymphoma models to provide a potential non-invasive method for monitoring CD38 in the clinic. Methods: Daratumumab was radiolabeled with 89Zr (t1/2 = 78.4 h) via conjugation with desferrioxamine (Df). After Western blot (WB) was used to screen CD38 expression in five lymphoma cell lines, flow cytometry and cellular binding assays were performed to test the binding ability of labeled or conjugated daratumumab with CD38 in vitro. PET imaging and biodistribution studies were performed to evaluate CD38 expression after injection of 89Zr-Df-daratumumab. 89Zr-Df-IgG was also evaluated as a non-specific control group in the Ramos model. Finally, CD38 expression in tumor tissues was verified by histological analysis. Results: Using WB screening, the Ramos cell line was found to express the highest level of CD38 while the HBL-1 cell line had the lowest expression. Df-conjugated and 89Zr-labeled daratumumab displayed similar high binding affinities with Ramos cells. PET imaging of 89Zr-Df-daratumumab showed a high tumor uptake of up to 26.6 ± 8.0 %ID/g for Ramos at 120 h post-injection, and only up to 6.6 ± 2.9 %ID/g for HBL-1 (n = 4). Additionally, 89Zr-Df-IgG demonstrated a low tumor uptake in the Ramos model (only 4.3 ± 0.8 %ID/g at 120 h post-injection). Ex vivo biodistribution studies showed similar trends with imaging results. Immunofluorescence staining of tumor tissues verified higher CD38 expression of Ramos than that of HBL-1. Conclusions: The role of 89Zr-Df-daratumumab was investigated for evaluating CD38 expression in lymphoma models non-invasively and was found to be to a promising imaging agent of CD38-positive hematological diseases such as MM in future clinical applications.

Original languageEnglish (US)
Pages (from-to)1372-1381
Number of pages10
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
Volume45
Issue number8
DOIs
StatePublished - Jul 1 2018

Keywords

  • B-cell lymphoma
  • CD38
  • Cancer
  • Daratumumab
  • ImmunoPET
  • Positron emission tomography (PET)
  • Zr

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'ImmunoPET imaging of CD38 in murine lymphoma models using <sup>89</sup>Zr-labeled daratumumab'. Together they form a unique fingerprint.

  • Cite this

    Kang, L., Jiang, D., England, C. G., Barnhart, T. E., Yu, B., Rosenkrans, Z. T., Wang, R., Engle, J. W., Xu, X., Huang, P., & Cai, W. (2018). ImmunoPET imaging of CD38 in murine lymphoma models using 89Zr-labeled daratumumab. European Journal of Nuclear Medicine and Molecular Imaging, 45(8), 1372-1381. https://doi.org/10.1007/s00259-018-3941-3